Polymyxin B (sulfate): High-Purity Antibiotic for Multidrug-Resistant Gram-Negative Bacteria

Executive Summary: Polymyxin B (sulfate) is a polypeptide antibiotic mixture, mainly comprising polymyxins B1 and B2, derived from Bacillus polymyxa strains, with a molecular weight of 1301.6 and a chemical formula of C₅₆H₉₈N₁₆O₁₃·H₂SO₄. It exhibits high bactericidal activity against multidrug-resistant Gram-negative organisms, especially Pseudomonas aeruginosa (APExBIO). Mechanistically, it disrupts bacterial cell membranes by acting as a cationic detergent. In vitro, it promotes dendritic cell maturation via upregulation of CD86 and HLA I/II, while activating ERK1/2 and NF-κB pathways (Yan et al., 2025). In animal models, it improves survival in bacteremia and reduces bacterial loads, but its nephrotoxicity and neurotoxicity necessitate careful use and monitoring.

Biological Rationale

Polymyxin B (sulfate) is a last-resort polypeptide antibiotic for combating multidrug-resistant Gram-negative bacteria. Its clinical relevance is underscored by increasing resistance to other antimicrobials and the rise of hospital-acquired infections. The compound is particularly effective against Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae (APExBIO product page). Its dual activity—antibacterial and immunomodulatory—enables researchers to model both infection clearance and immune cell maturation in vitro and in vivo. APExBIO’s C3090 formulation offers ≥95% purity, supporting reproducible results in sensitive assays. This article extends foundational concepts presented in "Polymyxin B (Sulfate): Redefining Immune Modulation and Microbiome Research" by providing updated reference data and workflow guidance for translational research.

Mechanism of Action of Polymyxin B (sulfate)

Polymyxin B acts as a cationic detergent. It binds to the lipid A component of lipopolysaccharides (LPS) in the outer membrane of Gram-negative bacteria. This interaction displaces stabilizing Ca²⁺ and Mg²⁺ ions, increasing membrane permeability and causing cell lysis. The bactericidal effect is rapid and concentration-dependent. In mammalian immune systems, Polymyxin B can promote dendritic cell maturation by upregulating co-stimulatory molecules such as CD86 and HLA class I/II. Intracellularly, it activates the ERK1/2 and IκB-α/NF-κB signaling pathways, as demonstrated in human dendritic cell assays (Yan et al., 2025).

Evidence & Benchmarks

• Polymyxin B (sulfate) demonstrates bactericidal activity against multidrug-resistant Pseudomonas aeruginosa in vitro at concentrations as low as 0.5–2 μg/ml (APExBIO, product page).
• In bacteremia mouse models, administration of Polymyxin B improves survival rates in a dose-dependent manner and reduces bacterial load within 24 hours post-infection (Yan et al., 2025).
• In vitro, Polymyxin B upregulates dendritic cell maturation markers (CD86, HLA I/II) and enhances ERK1/2 and NF-κB signaling in human immune cells (Yan et al., 2025).
• Solubility is up to 2 mg/ml in PBS (pH 7.2); solutions should be used short-term and stored at -20°C to maintain activity (APExBIO, product page).
• Nephrotoxicity and neurotoxicity are observed in mammals at elevated doses or with prolonged exposure, limiting clinical and experimental applications (Chempaign article).

This article clarifies mechanistic and workflow benchmarks beyond those in "Decoding Immune Modulation and Microbiome Interactions" by emphasizing storage, purity, and signaling pathway activation profiles.

Applications, Limits & Misconceptions

Polymyxin B (sulfate) is widely used in:

• Treatment of bloodstream, urinary tract, and meningitis infections caused by susceptible Gram-negative bacteria (APExBIO).
• Research on bacterial resistance mechanisms and Gram-negative sepsis models (CRISPR-CasX article).
• Dendritic cell maturation assays to study immunomodulation (Yan et al., 2025).
• Investigations into host-pathogen interactions and innate immune signaling.

Common Pitfalls or Misconceptions

• Polymyxin B is not effective against Gram-positive bacteria or most fungal pathogens except at non-clinically relevant concentrations.
• It should not be used as a first-line agent due to its nephrotoxicity and neurotoxicity risks.
• Long-term storage of working solutions (>24–48 hours) leads to loss of activity, even at -20°C.
• It does not reliably disrupt established biofilms in all Gram-negative species.
• Polymyxin B (sulfate) is not interchangeable with colistin (polymyxin E)—their pharmacodynamics and toxicity profiles differ.

Workflow Integration & Parameters

Researchers can integrate Polymyxin B (sulfate) into diverse workflows:

• Reconstitute powder in PBS (pH 7.2) at ≤2 mg/ml for immediate use; filter-sterilize if required.
• Store aliquots at -20°C; avoid repeated freeze-thaw cycles to preserve ≥95% purity and activity (APExBIO).
• For dendritic cell assays, use at 0.1–2 μg/ml, monitoring expression of maturation markers and signaling pathway activation (CD86, HLA I/II, ERK1/2, NF-κB).
• In murine sepsis or bacteremia models, dose and route should be titrated based on body weight, bacterial challenge, and study endpoints (Yan et al., 2025).

This guidance updates and expands the advanced protocols described in "Advanced Protocols for Gram-Negative Infection Models", highlighting the importance of high-purity APExBIO C3090 for reproducible immune and infection studies.

Conclusion & Outlook

Polymyxin B (sulfate) remains a critical tool for research on multidrug-resistant Gram-negative bacteria and host immune response modulation. High-purity formulations, such as APExBIO's C3090, enable precise and reliable integration into infection, immunity, and toxicity studies. Future work will continue to refine its applications in translational research, particularly in dissecting the mechanisms of immune cell maturation and signaling pathway activation. For detailed product specifications and ordering, refer to the official APExBIO product page.